News Details

BRANFORD, Conn.--(BUSINESS WIRE)--Sep. 4, 2024-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™ (“NGPS”) into their platform for developing novel gene therapies with improved targeting capabilities. Liberate is using the sequencer’s protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, with a simple readout of delivery and translation efficiency, dramatically increasing the precision, speed, and efficiency of their gene therapy discovery and development efforts.

Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation, at single-amino acid resolution. Quantum-Si’s protein barcoding application allows researchers to simultaneously tag, track, select, and measure a set of target proteins, with both in vitro and in vivo screening applications. And unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise.

The integration of Quantum-Si’s barcoding application into Liberate’s platform has already shown transformative potential.

“The integration of Platinum’s barcoding application into our workflow represents a significant step forward, allowing us to accelerate our discovery and screening efforts with reduced costs and shortened timelines. This innovation is helping us to push the boundaries of what is possible in the development of targeted genetic therapeutics,” said Walter Strapps, Ph.D., Chief Scientific Officer of Liberate Bio.

Liberate’s work with Platinum underscores the transformative impact that NGPS can have on the pharmaceutical and biotech industry, particularly in gene therapy and drug discovery. “Platinum’s barcoding application is revolutionizing the way researchers approach drug discovery and development. Liberate’s work exemplifies how this technology can unlock new possibilities in drug discovery, driving progress in the field,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si.

About Liberate Bio

Liberate Bio is a leading biotechnology company focused on revolutionizing drug discovery and development. With a commitment to innovation and precision, Liberate Bio utilizes advanced technologies to develop targeted therapeutics that address unmet medical needs. For more information, visit https://www.liberatebio.com/.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904162893/en/

Investor
Doug Farrell, VP, Investor Relations
ir@quantum-si.com

Media
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com

Source: Quantum-Si Incorporated